September 28, 2023 – After greater than a dozen reports of intestinal blockages in people taking the diabetes drug Ozempic, the FDA announced that the possibly life-threatening condition will likely be listed on the drug's label.
The medical term for intestinal obstruction is “ileus,” and the FDA has received 18 reports of this in people taking Ozempic.
The FDA received greater than 8,500 Reports of gastrointestinal problems in people doping up similar to Ozempic and Wegovy, the latter approved for weight reduction. Ileus is mentioned in 33 cases, including two deaths, wherein people took medications containing semaglutide, the energetic ingredient in Ozempic, Wegovy and one other widely used weight reduction drug called Mounjaro.
Semaglutide works by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which targets regions of the brain that regulate appetite and food intake. The package inserts for Mounjaro, Ozempic and Wegovy already mention that delayed gastric emptying may occur. Taking semaglutide is related to significant weight reduction, often within the range of 15% of body weight.
The FDA didn’t go up to now as to assert a direct link between Ozempic and intestinal obstruction.
“Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure,” the said the FDA when agreeing to the label update.
The same warning in regards to the risk of intestinal obstruction is already on the labels for Mounjaro And ways.
The label change comes after a lady from Louisiana Lawsuit filed It claims she was “seriously injured” after taking Mounjaro and Ozempic, and that the pharmaceutical corporations did not disclose the chance that the drugs could cause vomiting and diarrhea on account of inflammation of the stomach lining, in addition to the chance of stomach paralysis (often called gastroparesis).